CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen

NCT05312398 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

219

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Adenocarcinoma

Interventions

DRUG: Cetuximab
DRUG: FOLFIRI
DRUG: FOLFOX regimen
DRUG: Irinotecan

Sponsor

University of Campania Luigi Vanvitelli